

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/Caplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/Caplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	Caplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/Caplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN		Welcome Banner and News Items	
NEWS IPC8		For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:58:18 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:58:31 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-538196genA.str



```

chain nodes :
2 15 16 20
ring nodes :
1 3 4 5 6 7 8 12 13
chain bonds :
1-2 2-5 13-16 13-20 15-16
ring bonds :
1-12 1-13 3-4 3-8 4-5 5-6 6-7 7-8 12-13
exact/norm bonds :
1-12 1-13 2-5 3-4 3-8 4-5 5-6 6-7 7-8 12-13 13-20 15-16
exact bonds :
1-2 13-16

```

G1:Cb,Cy,Hy,Ak

G2:C,S,N,Cb,Cy,Hy

G3:Cb,Cy,Hy,Ak


```

Match level :
1:Atom 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 12:Atom 13:Atom
15:CLASS 16:CLASS 20:CLASS

```

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



G1 Cb,Cy,Hy,Ak
 G2 C, S, N, Cb, Cy, Hy
 G3 Cb, Cy, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
 FULL SEARCH INITIATED 17:59:07 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1885257 TO ITERATE

51.4% PROCESSED 968672 ITERATIONS 217 ANSWERS

53.0% PROCESSED 1000000 ITERATIONS 217 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.23

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: 1885257 TO 1885257
 PROJECTED ANSWERS: 349 TO 469

L2 217 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	179.28	179.49

FILE 'CAPLUS' ENTERED AT 18:00:12 ON 17 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

L3 8 L2

=> d 13 1-8 abs ibib hitstr

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB There is considerable interest in developing KOP Opioid receptor ligands as clin. useful analgesics. Moreover, compds. with mixed KOP receptor and mu-opioid peptide (MOP) receptor agonist/antagonist properties could have a better therapeutic potential. The benzomorphan-based synthetic ligands MPCB and CCB have been shown to bind KOP receptors with high affinity and selectivity. We report here a series of compds. synthesized to perform structure-affinity relationship (SAR) studies on MPCB. The aim of this study was to optimize KOP receptor-ligand interaction and to modulate MOP receptor selectivity. In the benzylamide analog of MPCB (compound 9) the presence of a third aromatic nucleus, at an appropriate distance and conformation with respect to aromatic pharmacophoric residues, increased KOP receptor affinity by about 6-fold compared to MPCB ($K_i = 35$ nM and $K_i = 240$ nM, resp.). Instead, compound 28 with a tertiary amino group in the nitrogen substituent displayed a comparable KOP receptor affinity ($K_i = 179$ nM) but also high MOP receptor affinity ($K_i = 45$ nM). Thus, the present study shows that in benzomorphan-based ligands the presence of different functional groups in the nitrogen substituent, ranging from a pos. charged amine to an addnl. aromatic ring, is able to promote the correct alignment of aromatic pharmacophoric residues with MOP and KOP receptor types. Evaluation of docking simulations of compds. 9 and 28 into the KOP and MOP receptor displayed selective ligand interactions with the important amino acid residues Tyr320 (TMVII) and Trp318 (TMVII), resp.

ACCESSION NUMBER: 2007:1311715 CAPLUS

DOCUMENT NUMBER: 148:112285

TITLE: New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands

AUTHOR(S): Pasquinucci, L.; Iadanza, M.; Marrazzo, A.;
Prezzavento, O.; Ronsisvalle, S.; Scoto, G. M.;
Parenti, C.; De Luca, L.; Ronsisvalle, G.

CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of
Catania, Italy

SOURCE: Farmazie (2007), 62(11), 813-824

CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 1001017-64-6P 1001017-66-8P 1001017-68-0P
1001017-69-1P 1001017-70-4P 1001017-72-6P
1001017-74-8P 1001017-76-0P 1001017-78-2P
1001017-80-6P 1001017-82-8P 1001017-86-2P
1001017-88-4P 1001017-90-8P 1001017-92-0P
1001017-94-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(New benzomorphan derivs. of MPCB as MOP and KOP receptor ligands)

RN 1001017-64-6 CAPLUS


CN Cyclopropanecarboxamide, 1-phenyl-N-[(1R)-1-phenylethyl]-2-[[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-63-5

CMF C33 H38 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-66-8 CAPLUS


CN Cyclopropanecarboxamide, 1-phenyl-N-(phenylmethyl)-2-[[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-65-7

CMF C32 H36 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-68-0 CAPLUS


CN Cyclopropanecarboxamide, N,N-diethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl)methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-67-9

CMF C29 H38 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 1001017-69-1 CAPLUS

CN Cyclopropanecarboxamide, N-methyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1001017-70-4 CAPLUS

CN Cyclopropanecarboxamide, N-ethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1001017-72-6 CAPLUS


CN Cyclopropanecarboxamide, 1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-71-5

CMF C25 H30 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-74-8 CAPLUS


CN Cyclopropanecarboxamide, N,N-dimethyl-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-73-7

CMF C27 H34 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-76-0 CAPLUS


CN Cyclopropanecarboxamide, N,1-diphenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]-, (1S,2R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-75-9

CMF C31 H34 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 1001017-78-2 CAPLUS
 CN Methanone, [(1S,2R)-1-phenyl-2-[[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]cyclopropyl]-1-pyrrolidinyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-77-1
 CMF C29 H36 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 1001017-80-6 CAPLUS
 CN Methanone, [(1S,2R)-1-phenyl-2-[[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl]methyl]cyclopropyl]-1-piperidinyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-79-3
 CMF C30 H38 N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-82-8 CAPLUS


CN Methanone, 4-morpholinyl[(1S,2R)-1-phenyl-2-[[(2R,6R,11R)-1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-3(2H)-yl)methyl]cyclopropyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-81-7

CMF C29 H36 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-86-2 CAPLUS


CN 2,6-Methano-3-benzazocin-8-ol, 3-[[(1R,2S)-2-[(acetyloxy)methyl]-2-phenylcyclopropyl)methyl]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-, (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-85-1

CMF C27 H33 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-88-4 CAPLUS


CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-[[[(1R,2S)-2-(hydroxymethyl)-2-phenylcyclopropyl]methyl]-6,11-dimethyl-, (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-87-3

CMF C25 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-90-8 CAPLUS

CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-[[[(1R,2S)-2-phenyl-2-(1-pyrrolidinylmethyl)cyclopropyl]methyl]-,


(2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-89-5

CMF C29 H38 N2 O

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 1001017-92-0 CAPLUS


CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-
[[(1R,2S)-2-phenyl-2-(1-piperidinylmethyl)cyclopropylmethyl]-,
(2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 1001017-91-9

CMF C30 H40 N2 O

Absolute stereochemistry. Rotation (-).



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 1001017-94-2 CAPLUS
 CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-
 [{(1R,2S)-2-(4-morpholinylmethyl)-2-phenylcyclopropyl)methyl]-,
 (2R,6R,11R)-, ethanedioate (1:1) (CA INDEX NAME)
 CM 1
 CRN 1001017-93-1
 CMF C29 H38 N2 O2

Absolute stereochemistry. Rotation (-).





CM 2
 CRN 144-62-7
 CMF C2 H2 O4



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 GI



II

AB Disclosed are compds. according to formula I: wherein the variables are defined herein. Compds. of formula I wherein R is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, etc.; R1 is (un)substituted Ph, (un)substituted (mono/bi)cyclic heteroaryl and (un)substituted C3-7 cycloalkyl; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and Y are attached to carbon or nitrogen in ring A via 1,2- or 1,3- or 1,4-relationship; Q is CO, CS, SO2, C=CH-NO2, C=N-CN, dioxocyclobutenylene, etc.; W is a bond and (un)substituted C1-5 alkylene; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is H, C1-6 alkyl, C4-7 heterocyclyl, OH, NH2 and derivs., etc.; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Such compds. are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to formula I. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity (some data given).

ACCESSION NUMBER: 2007:1177123 CAPLUS
DOCUMENT NUMBER: 147:469237
TITLE: Acylpiperidine compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Cacatian, Salvacion; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.; Flaherty, Patrick T.; Kallander, Lara S.; Leach, Colin A.; Lawhorn, Brian; Lu, Qing; Terrell, Lamont R.; Ghavini-Alagha, Bahman; Zhang, Jing; Ghirlanda, Damiano; Hou, Xiaoping; Semus, Simon
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 619pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117482	A2	20071018	WO 2007-US8339	20070405
WO 2007117482	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			US 2006-789703P	P 20060405
			US 2006-789823P	P 20060405

OTHER SOURCE(S): MARPAT 147:469237


IT 952706-35-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylpiperidine compds. as aspartic protease inhibitors including renin inhibitors useful in treatment of diseases - associated with aspartic protease activity)



RN 952706-35-3 CAPLUS

CN Methanone, [(3R)-3-[(1S)-1-(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)-1-hydroxy-5-methoxypentyl]-1-piperidinyl][(1R,2R)-2-methyl-2-[(methylamino)methyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
GI



II

AB Described are compds. of formula I, which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compds. described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. Compds. of formula I wherein R is C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C2-7 cycloalkenyl, etc.; R1 is Ph, (mono/bi)cyclic heteroaryl, benzo-1,3-dioxole, benzo-1,3-dioxin, etc.; X and Y are independently CH2 and a single bond; R2 is H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 alkylthio, etc.; R3 is H, halo, C1-6 alkyl, C1-6 alkoxy, OH, etc.; A is (un)substituted (un)saturated (un)bridge 4- to 7-membered ring; Q and U are attached to carbon or nitrogen atoms in ring A in a 1,2 or 1,3 or 1,4 relationship; Q is CO, CS, SO2, C=C-NO2, C=N-CN, dioxocyclobutylene, etc.; E is (un)substituted (un)saturated (un)bridge 3- to 7-membered ring; G is OH, C1-6 hydroxyalkyl, amino, C1-6 aminoalkyl, C(=NH)NH2 and derivs., etc.; and their enantiomers, diastereoisomers and salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their renin inhibitory activity.

ACCESSION NUMBER: 2007:1177122 CAPLUS
DOCUMENT NUMBER: 147:469236
TITLE: Piperidinyl pyrrolidinyl methanone compounds as renin inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases associated with aspartic protease activity
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Tice, Colin M.; Cacatian, Salvacion; Dillar, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Mcgeehan, Gerard; Zhao, Wei; Simpson, Robert D.; Singh, Suresh B.
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 328pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117559	A2	20071018	WO 2007-US8520	20070405
WO 2007117559	A3	20071129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,

GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
 KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-789703P P 20060405
 US 2006-789823P P 20060405

OTHER SOURCE(S): MARPAT 147:469236

IT 952706-35-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrrolidinyl piperidinyl methanone compds.
 as aspartic protease inhibitors including renin inhibitors useful in
 treatment of diseases - associated with aspartic protease activity)

RN 952706-35-3 CAPLUS

CN Methanone, [(3R)-3-[(1S)-1-(6-fluoro-3'-methyl[1,1'-biphenyl]-2-yl)-1-
 hydroxy-5-methoxypentyl]-1-piperidinyl][(1R,2R)-2-methyl-2-
 [(methylamino)methyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB The aim of the present study was to investigate the biol. profile of new
 substituted 1-phenyl-2-cyclopropylmethylamines. High affinity for both
 σ subtypes was achieved when 4-phenylpiperidin-4-ol (4a-e) and
 4-benzylpiperidine moieties were present (5a-e).
 (1R,2S/1S,2R)-2-[4-Hydroxy-(4-phenylpiperidin-1-yl)methyl]-1-(4-
 methylphenyl)cyclopropanecarboxylate (4b) showed high affinity for the
 σ_1 sites ($K_i = 1.5$ nM) and the most favorable σ_1/σ_2
 selectivity ($K_i(\sigma_2)/K_i(\sigma_1) = 33.9$). Binding affinity studies
 showed that 4b binding on N-methyl-D-aspartate (NMDA), dopaminergic (D1,
 D2, D3), muscarinic, histaminergic H1, adrenergic (α_1 , α_2),
 serotonergic (5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT6), DA (DAT), and 5-HT
 (SERT) transporters was not significant. Interestingly, σ ligands
 differently induced the expression of tissue transglutaminase (TG-2) in
 primary astroglial cell cultures. We suggest that 4b may act as a
 σ_1/σ_2 agonist and that the σ ligands may modulate TG-2
 differently.


ACCESSION NUMBER: 2007:160316 CAPLUS

DOCUMENT NUMBER: 146:394316

TITLE: Novel Sigma Receptor Ligands: Synthesis and Biological


AUTHOR(S): Profile
 Prezzavento, Orazio; Campisi, Agata; Ronsisvalle, Simone; Li Volti, Giovanni; Marrazzo, Agostino; Bramanti, Vincenzo; Cannavo, Giuseppe; Vanella, Luca; Cagnotto, Alfredo; Mennini, Tiziana; Ientile, Riccardo; Ronsisvalle, Giuseppe
 CORPORATE SOURCE: Department of Pharmaceutical Sciences and Department of Biological Chemistry Medical Chemistry and Molecular Biology, University of Catania, Catania, 95125, Italy
 SOURCE: Journal of Medicinal Chemistry (2007), 50(5), 951-961
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:394316
 IT 932737-00-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Novel Sigma Receptor Ligands: Synthesis and Biol. Profile)
 RN 932737-00-3 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-(4-methylphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 932736-89-5P 932736-91-9P 932736-94-2P
 932736-95-3P 932736-97-5P 932736-99-7P
 932737-01-4P 932737-03-6P 932737-05-8P
 932737-07-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Novel Sigma Receptor Ligands: Synthesis and Biol. Profile)
 RN 932736-89-5 CAPLUS
 CN Cyclopropanecarboxylic acid, 2-[[4-(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-phenyl-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)
 CM 1
 CRN 932736-88-4
 CMF C23 H27 N O3

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 932736-91-9 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-methylphenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-90-8

CMF C24 H29 N O3

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 932736-94-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-methoxyphenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-93-1

CMF C24 H29 N O4

Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 932736-95-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-(4-chlorophenyl)-2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-, methyl ester, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 932736-97-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[(4-hydroxy-4-phenyl-1-piperidinyl)methyl]-1-(4-nitrophenyl)-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932736-96-4

CMF C23 H26 N2 O5

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 932736-99-7 CAPLUS


CN Cyclopropanecarboxylic acid, 1-phenyl-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (5:4) (CA INDEX NAME)

CM 1

CRN 932736-98-6

CMF C24 H29 N O2

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 932737-01-4 CAPLUS


CN Cyclopropanecarboxylic acid, 1-(4-methylphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (4:5) (CA INDEX NAME)

CM 1

CRN 932737-00-3

CMF C25 H31 N O2

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 932737-03-6 CAPLUS


CN Cyclopropanecarboxylic acid, 1-(4-methoxyphenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-02-5

CMF C25 H31 N O3

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 932737-05-8 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-(4-chlorophenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-04-7
 CMF C24 H28 Cl N O2

Relative stereochemistry.



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 932737-07-0 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-(4-nitrophenyl)-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester, (1R,2S)-rel-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 932737-06-9
 CMF C24 H28 N2 O4

Relative stereochemistry.



CM 2

CRN 144-62-7
 CMF C2 H2 O4

PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 237pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007010383	A1	20070125	WO 2006-IB2016	20060724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006271297	A1	20070125	AU 2006-271297	20060724
CA 2616079	A1	20070125	CA 2006-2616079	20060724
EP 1908753	A1	20080409	EP 2006-779892	20060724
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
IN 2008DN00551	A	20080711	IN 2008-DN551	20080121
MX 200801048	A	20080502	MX 2008-1048	20080122
CN 101228131	A	20080723	CN 2006-80026802	20080122
KR 2008031971	A	20080411	KR 2008-704378	20080222
PRIORITY APPLN. INFO.:			JP 2005-213534	A 20050722
			JP 2005-330890	A 20051115
			JP 2006-45985	A 20060222
			WO 2006-IB2016	W 20060724

OTHER SOURCE(S): MARPAT 146:163039

IT 920332-65-6P, (E)-2-[7-Trifluoromethyl-2,3-dihydro-1-[(2,2-dimethylcyclopropyl)carbonyl]quinolin-4(1H)-ylidene]-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 2-(bicyclic heterocyclidene)acetamide derivs. as antagonists of transient receptor potential type 1 (TRPV1) for treatment or prevention of pains)

RN 920332-65-6 CAPLUS

CN Acetamide, 2-[1-[(2,2-dimethylcyclopropyl)carbonyl]-2,3-dihydro-7-(trifluoromethyl)-4(1H)-quinolinyldiene]-N-(5,6,7,8-tetrahydro-7-hydroxy-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB Two efficient, simple, cheap, and environmentally benign preps. of cyclopropanes were achieved. One was the formation via 3-exo-trig manner from various electron-deficient 2-iodoethyl-substituted olefins with zinc powder in a mixture of t-Bu alc. and water, and the other was the formation via 3-exo-tet manner from various 1,3-dihalopropanes with zinc powder in ethanol.

ACCESSION NUMBER: 2005:1008949 CAPLUS

DOCUMENT NUMBER: 143:459781

TITLE: Facile preparation of cyclopropanes from 2-iodoethyl-substituted olefins and 1,3-dihalopropanes with zinc powder

AUTHOR(S): Sakuma, Daisuke; Togo, Hideo

CORPORATE SOURCE: Graduate School of Science and Technology, Chiba University, Yayoi-cho 1-33, Inage-ku, Chiba, 263-8522, Japan

SOURCE: Tetrahedron (2005), 61(42), 10138-10145

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:459781


IT 827574-06-1P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of cyclopropanes via zinc-mediated cyclopropanation of haloethyl-substituted olefins, iodomethylcyclohexanecarboxaldehyde, or dihalopropanes)

RN 827574-06-1 CAPLUS

CN Ethanone, 2-(2,2-dimethylcyclopropyl)-1-(1-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB The present invention relates to cyclopropyl derivs. of formula (I) or salts thereof such as pharmaceutically acceptable salts [wherein R1-R5 = independently H, halogen, cyano, nitro, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6 alk(en/yn)yl, amino, C1-6 alk(en/yn)ylamino, di[C1-6-alk(en/yn)yl]amino, C1-6 alk(en/yn)ylcarbonyl, aminocarbonyl, C1-6-alk(en/yn)ylaminocarbonyl, di[C1-6 alk(en/yn)ylaminocarbonyl, hydroxy, C1-6 alk(en/yn)ylloxy, C1-6-alk(en/yn)ylthio, halo-C1-6 alk(en/yn)yl, halo-C1-6 alk(en/yn)ylsulfonyl, halo-C1-6 alk(en/yn)ylsulfanyl, and C1-6 alk(en/yn)ylsulfonyl; R6 = H, halo-C1-6 alk(en/yn)yl, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6 alk(en/yn)yl; R7 = aryl, heteroaryl, aryl-CR8R9- (wherein R8, R9 = H, C1-6 alk(en/yn)yl, C3-8 cycloalk(en)yl, C3-8 cycloalk(en)yl-C1-6 alk(en/yn)yl); n = 0-2; Q = Q1, Q2, Q3, etc.; R10, R12 = aryl; R11 = aryl, benzyl, halo-C1-6 alk(en/yn)ylsulfonyl, C1-6 alk(en/yn)ylsulfonyl, arylsulfonyl, arylacyl, C1-6-alk(en/yn)ylcarbonyl, aminocarbonyl, etc.; R13 = H, HO, cyano, or NH2, etc.]. These compds. are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, including psychotic disorders, schizophrenia, depression, anxiety, Parkinson's disease, pain, convulsions, cough, asthma, airway hyperresponsiveness, microvascular hypersensitivity, bronchoconstriction, gut inflammation, inflammatory bowel disease, hypertension, imbalances in water and electrolyte homeostasis, ischemia, edema, plasma extravasation, and obesity. For example, (1S,2R)-2-(4-acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide had an apparent NK3 affinity (Ki) of less than 50 nM in using a membrane prepared from baby hamster cells stably expressing the human NK3 receptor.

ACCESSION NUMBER: 2005:158639 CAPLUS

DOCUMENT NUMBER: 142:261403

TITLE: Preparation of 1-phenylcyclopropane-1-carboxamide

INVENTOR(S): Kehler, Jan; Hansen, Tore; Poulsen, Anders; Bjornholm, Berith; Ruhland, Thomas; Norgaard, Morten Bang; Nielsen, Soren Moller

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016884	A1	20050224	WO 2004-DK538	20040813
WO 2005016884	A9	20060316		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004265020	A1	20050224	AU 2004-265020	20040813
CA 2535646	A1	20050224	CA 2004-2535646	20040813
EP 1656349	A1	20060517	EP 2004-739035	20040813
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004013584	A	20061017	BR 2004-13584	20040813
CN 1867549	A	20061122	CN 2004-80029691	20040813
JP 2007502253	T	20070208	JP 2006-522897	20040813
MX 2006PA01738	A	20060512	MX 2006-PA1738	20060214
IN 2006CN00544	A	20070622	IN 2006-CN544	20060214
NO 2006001137	A	20060309	NO 2006-1137	20060309
US 20060281746	A1	20061214	US 2006-568483	20060814
PRIORITY APPLN. INFO.:			DK 2003-1175	A 20030815
			US 2003-501535P	P 20030908
			WO 2004-DK538	W 20040813

OTHER SOURCE(S): CASREACT 142:261403; MARPAT 142:261403

IT 846060-64-8P 846060-65-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)

RN 846060-64-8 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-, methyl ester, (1S,2R)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 846060-63-7

CMF C25 H28 Cl2 N2 O3

Absolute stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 846060-65-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-, hydrochloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 846060-75-1P, (1S,2S)-2-[(E)-3-(4-Acetylamino-4-phenylpiperidin-1-yl)-1-propenyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)

RN 846060-75-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1E)-3-[4-(acetylamino)-4-phenyl-1-piperidinyl]-1-propen-1-yl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 846059-18-5P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-19-6P, (1S,2R)-2-[[4-[(Acetyl) (methyl) amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-20-9P 846059-21-0P 846059-22-1P 846059-23-2P 846059-24-3P, (1S,2R)-1-Phenyl-2-[[4-phenyl-4-[(piperidin-1-yl) carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-25-4P 846059-26-5P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-27-6P, (1S,2R)-2-[[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-1-yl]methyl]-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-28-7P 846059-29-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-30-1P, (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl) carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-31-2P, (1S,2R)-2-[[4-[(Acetyl) (methyl) amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-32-3P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-33-4P 846059-34-5P 846059-35-6P 846059-36-7P 846059-37-8P 846059-38-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-39-0P, (1S,2R)-2-[[4-[(Acetyl) (methyl) amino]-4-phenylpiperidin-1-yl]methyl]-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-41-4P 846059-43-6P, (1S,2R)-2-[4-(4-Chloro-3-trifluoromethylphenyl)-4-hydroxypiperidin-1-ylmethyl]-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-44-7P 846059-45-8P, (1S,2R)-2-[[4-[(Acetyl) (methyl) amino]-4-phenylpiperidin-1-yl]methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-48-1P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-50-5P 846059-52-7P 846059-54-9P, (1S,2R)-1-(4-Fluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl) carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-56-1P 846059-58-3P, (1S,2R)-1-(3,4-Difluorophenyl)-2-[[4-phenyl-4-

[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid methylamide 846059-61-8P 846059-62-9P,
 (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-63-0P,
 (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-64-1P 846059-65-2P 846059-66-3P
 846059-67-4P 846059-68-5P,
 (1S,2R)-1-Phenyl-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-69-6P, (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-70-9P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-71-0P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-72-1P,
 (1S,2R)-1-(4-Chlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-73-2P,
 (1S,2R)-2-[[4-(Acetyl) (methyl)amino]-4-phenylpiperidin-1-yl)methyl]-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-74-3P 846059-75-4P,
 (1S,2R)-2-[[4-(Acetyl) (methyl)amino]-4-phenylpiperidin-1-yl)methyl]-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-76-5P, (1S,2R)-2-[[4-(Acetyl) (methyl)amino]-4-phenylpiperidin-1-yl)methyl]-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-77-6P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-78-7P,
 (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl)methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-79-8P,
 (1S,2R)-2-[[4-(Acetyl) (methyl)amino]-4-phenylpiperidin-1-yl)methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846059-80-1P
 846059-81-2P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-82-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid (1-methyl-1-phenylethyl)amide 846059-83-4P,
 (1S,2R)-2-(4-Phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-ethylamide 846059-84-5P, (1R,2S)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-85-6P,
 (1R,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-86-7P, (1S,2S)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-87-8P 846059-88-9P
 846059-89-0P 846059-90-3P 846059-91-4P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-benzyl-N-methylamide 846059-92-5P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-phenylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide 846059-93-6P 846059-94-7P,
 (1S,2R)-2-[[4-(Acetyl) (methyl)amino]-4-phenylpiperidin-1-yl)methyl]-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide

846059-95-8P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-fluorophenyl)cyclopropanecarboxylic acid
 N-(4-fluorobenzyl)-N-methylamide 846059-96-9P
 846059-97-0P, (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid
 N-(4-fluorobenzyl)-N-methylamide 846059-98-1P
 846059-99-2P 846060-00-2P,
 (1S,2R)-2-(4-Acetyl-4-phenylpiperidin-1-ylmethyl)-1-(4-chlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide
 846060-01-3P 846060-02-4P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-fluorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide
 846060-03-5P, (1S,2R)-1-(4-Fluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-04-6P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-difluorophenyl)cyclopropanecarboxylic acid
 N-(2-chlorobenzyl)-N-methylamide 846060-06-8P,
 (1S,2R)-1-(3,4-Difluorophenyl)-2-[[4-phenyl-4-[(piperidin-1-yl)carbonyl]piperidin-1-yl]methyl]cyclopropanecarboxylic acid N-(2-chlorobenzyl)-N-methylamide 846060-07-9P
 846060-08-0P 846060-09-1P 846060-10-4P
 846060-11-5P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid phenylamide
 846060-19-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid benzylamide
 846060-20-6P 846060-21-7P 846060-22-8P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(2-chlorobenzyl)amide
 846060-23-9P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-(3,4-dichlorobenzyl)amide 846060-24-0P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-methyl-N-phenylamide
 846060-25-1P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-methoxyphenyl)cyclopropanecarboxylic acid
 N-(4-fluorobenzyl)-N-methylamide 846060-26-2P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-p-tolylcyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
 846060-27-3P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-m-tolylcyclopropanecarboxylic acid N-benzyl-N-methylamide
 846060-28-4P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-m-tolylcyclopropanecarboxylic acid
 N-(4-fluorobenzyl)-N-methylamide 846060-29-5P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-methoxyphenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
 846060-30-8P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(4-methoxyphenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide 846060-31-9P,
 (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-p-tolylcyclopropanecarboxylic acid N-benzyl-N-methylamide
 846060-32-0P, (1S,2R)-2-(4-Acetylamino-4-phenylpiperidin-1-ylmethyl)-1-(3-methoxyphenyl)cyclopropanecarboxylic acid
 N-benzyl-N-methylamide 846060-33-1P,
 (1S,2R)-1-Phenyl-2-(4-phenyl-4-ureidopiperidin-1-ylmethyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
 846060-34-2P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-phenyl-4-ureidopiperidin-1-yl]methyl]cyclopropanecarboxylic acid
 N-benzyl-N-methylamide 846060-35-3P,
 (1S,2R)-1-Phenyl-2-[4-(N'-methylureido)-4-phenylpiperidin-1-ylmethyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
 846060-36-4P, (1S,2R)-2-[4-(N'-Methylureido)-4-phenylpiperidin-1-

ylmethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-benzyl-N-methylamide 846060-37-5P,
N-[1-[[[(1S,2R)-2-[(4-Fluorobenzyl)(methyl)carbamoyl]-2-phenylcyclopropyl]methyl]-4-phenylpiperidin-4-yl]oxalamide
846060-38-6P, N-[1-[[[(1S,2R)-2-(N-Benzyl-N-methylcarbamoyl)-2-(3,4-dichlorophenyl)cyclopropyl]methyl]-4-phenylpiperidin-4-yl]oxalamide
846060-39-7P, (1S,2R)-1-Phenyl-2-[[4-[(methylsulfonyl)amino]-4-phenylpiperidin-1-yl]methyl]cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-40-0P,
(1S,2R)-2-[[4-[(Methylsulfonyl)amino]-4-phenylpiperidin-1-yl]methyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid N-benzyl-N-methylamide
846060-41-1P, [1-[[[(1S,2R)-2-[N-(4-Fluorobenzyl)-N-methylcarbamoyl]-2-phenylcyclopropyl]methyl]-4-phenylpiperidin-4-yl]carbamic acid methyl ester 846060-42-2P,
[1-[[[(1S,2R)-2-(N-Benzyl-N-methylcarbamoyl)-2-(3,4-dichlorophenyl)cyclopropyl]methyl]-4-phenylpiperidin-4-yl]carbamic acid methyl ester 846060-43-3P,
(1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-(N',N'-dimethylureido)-4-phenylpiperidin-1-yl]methyl]cyclopropanecarboxylic acid
N-benzyl-N-methylamide 846060-44-4P,
(1S,2R)-1-Phenyl-2-[4-(N',N'-dimethylureido)-4-phenylpiperidin-1-ylmethyl]cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
846060-45-5P, (1S,2R)-2-[2-(4-Acetylmino-4-phenylpiperidin-1-yl)ethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-46-6P,
(1S,2R)-2-[3-(4-Acetylmino-4-phenylpiperidin-1-yl)propyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-47-7P,
(1S,2R)-2-[4-(2-Acetylmino-5-fluorophenyl)piperidin-1-ylmethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-48-8P,
(1S,2R)-2-(4-Acetylmino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dimethylphenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-49-9P,
(1S,2R)-2-(4-Acetylmino-4-phenylpiperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-50-2P,
(1S,2R)-2-(4-Acetylmino-4-phenylpiperidin-1-ylmethyl)-1-(3-chlorophenyl)cyclopropanecarboxylic acid N-(4-fluorobenzyl)-N-methylamide
846060-51-3P, (1S,2R)-2-(4-Acetylmino-4-phenylpiperidin-1-ylmethyl)-1-(3-fluorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide 846060-52-4P,
(1S,2R)-1-(3,4-Dichlorophenyl)-2-[(4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid
N-methyl-N-(naphthalen-1-ylmethyl)amide 846060-53-5P
846060-54-6P, (1S,2R)-1-(3,4-Dichlorophenyl)-2-[[4-(4-Acetylmino-4-phenylpiperidin-1-yl)methyl]cyclopropanecarboxylic acid
N-methyl-N-(naphthalen-1-ylmethyl)amide 846060-76-2P,
(1S,2S)-2-[2-(4-Acetylmino-4-phenylpiperidin-1-yl)ethyl]-1-(3,4-dichlorophenyl)cyclopropanecarboxylic acid
N-(4-fluorobenzyl)-N-methylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenylcyclopropane-1-carboxamide derivs. as tachykinin NK3 receptor antagonists)
RN 846059-18-5 CAPLUS
CN Cyclopropanecarboxamide, 2-[[4-(acetylmino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-19-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-20-9 CAPLUS


CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-21-0 CAPLUS
 CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 846059-22-1 CAPLUS
 CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-23-2 CAPLUS
 CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-24-3 CAPLUS
 CN Cyclopropanecarboxamide, N-methyl-1-phenyl-N-(phenylmethyl)-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-25-4 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-26-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-27-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl)methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-28-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-29-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-30-1 CAPLUS

CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-31-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-32-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-33-4 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-34-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 846059-35-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-difluorophenyl)-N-methyl-N-(1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 846059-36-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-difluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-37-8 CAPLUS


CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 846059-38-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-39-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-41-4 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-43-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-44-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-45-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-48-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-50-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-

methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-52-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-54-9 CAPLUS

CN Cyclopropanecarboxamide, 1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-2-[(4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-56-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-58-3 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-difluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-61-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(4-

fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-62-9 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-
2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 846059-63-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-
(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-64-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 846059-65-2 CAPLUS


CN Cyclopropanecarboxamide, 2-[[4-(acetamino)-4-phenyl-1-piperidinylmethyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 846059-66-3 CAPLUS
 CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-67-4 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-68-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-69-6 CAPLUS

CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-70-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-

, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-71-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-72-1 CAPLUS

CN Cyclopropanecarboxamide, 1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-73-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-74-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-75-4 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl)methyl]-N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-76-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-77-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-78-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-79-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-80-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-81-2 CAPLUS

CN Cyclopropanecarboxamide, 1-((3,4-dichlorophenyl)(N-methyl-N-(phenylmethyl)-2-[(4-phenyl-1-piperidinyl)methyl]amino)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-82-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetamido)-4-phenyl-1-piperidinylmethyl]-1-((3,4-dichlorophenyl)(N-(1-methyl-1-phenylethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-83-4 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-ethyl-N-(phenylmethyl)-2-
[[4-phenyl-1-piperidinyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-84-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-85-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1R,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-86-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-87-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 846059-88-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-89-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 846059-90-3 CAPLUS


CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-[(1R)-1-phenylethyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-91-4 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-methyl-1-phenyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846059-92-5 CAPLUS
 CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-93-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-94-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylmethylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846059-95-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 846059-96-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-97-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(3,4-difluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-98-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846059-99-2 CAPLUS

CN Cyclopropanecarboxamide, 1-(4-fluorophenyl)-N-methyl-N-[(1S)-1-phenylethyl]-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinylmethyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-00-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[(4-acetyl-4-phenyl-1-piperidinyl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-01-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-02-4 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetyl-amino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-03-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(4-fluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-04-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-06-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-2-[[4-phenyl-4-(1-piperidinylcarbonyl)-1-piperidinyl]methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-07-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-08-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-difluorophenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-09-1 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,4-dichlorophenyl)methyl]-2-[(4-phenyl-1-piperidyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-10-4 CAPLUS


CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-[(3,4-dimethoxyphenyl)methyl]-2-[(4-phenyl-1-piperidyl)methyl]-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-11-5 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-19-3 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-20-6 CAPLUS
 CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-difluorophenyl)-N-[(2-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-21-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinylmethyl]-1-(3,4-dichlorophenyl)ethyl]-N-[1-(4-methoxyphenyl)ethyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-22-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinylmethyl]-N-[(2-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-23-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(3,4-dichlorophenyl)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-24-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-25-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-1-(4-methoxyphenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-26-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-

piperidinyl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-(4-methylphenyl)-
, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-27-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl)methyl]-N-methyl-1-(3-methylphenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-28-4 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-(3-methylphenyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-29-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-1-(3-methoxyphenyl)-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-30-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(4-methoxyphenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-31-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-N-methyl-1-(4-methylphenyl)-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-32-0 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetlamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-methoxyphenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-33-1 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-[(aminocarbonyl)amino]-4-phenyl-1-piperidinyl]methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-34-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-[(aminocarbonyl)amino]-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-35-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-[[[(methylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-36-4 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-2-[[4-[[[(methylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]methyl]-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-37-5 CAPLUS

CN Ethanediamide, N1-[1-[[[(1S,2R)-2-[[[(4-fluorophenyl)methyl]methylamino]carbonyl]-2-phenylcyclopropyl]methyl]-4-phenyl-4-piperidinyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-38-6 CAPLUS

CN Ethanediamide, N1-[1-[[1-(1S,2R)-2-(3,4-dichlorophenyl)-2-[[methyl(phenylmethyl)amino]carbonyl]cyclopropyl]methyl]-4-phenyl-1-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-39-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(4-fluorophenyl)methyl]-N-methyl-2-[[4-[(methylsulfonyl)amino]-4-phenyl-1-piperidinyl]methyl]-1-phenyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-40-0 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-2-[[4-[(methylsulfonyl)amino]-4-phenyl-1-piperidinyl]methyl]-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-41-1 CAPLUS

CN Carbamic acid, [1-[[[(1S,2R)-2-[[[(4-fluorophenyl)methyl]methylamino]carbonyl]-2-phenylcyclopropyl)methyl]-4-phenyl-4-piperidiny]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-42-2 CAPLUS

CN Carbamic acid, [1-[[[(1S,2R)-2-(3,4-dichlorophenyl)-2-[[methyl(phenylmethyl)amino]carbonyl]cyclopropyl)methyl]-4-phenyl-4-piperidiny]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-43-3 CAPLUS


CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-2-[[[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidiny]methyl]-N-methyl-N-(phenylmethyl)-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-44-4 CAPLUS
 CN Cyclopropanecarboxamide, 2-[[4-[(dimethylamino)carbonylamino]-4-phenyl-1-piperidinyl)methyl]-N-[(4-fluorophenyl)methyl]-N-methyl-1-phenyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 846060-45-5 CAPLUS
 CN Cyclopropanecarboxamide, 2-[2-[4-(acetylamino)-4-phenyl-1-piperidinyl]ethyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 846060-46-6 CAPLUS
 CN Cyclopropanecarboxamide, 2-[3-[4-(acetylamino)-4-phenyl-1-piperidinyl]propyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-47-7 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-[2-(acetylamino)-5-fluorophenyl]-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-48-8 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dimethylphenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-49-9 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-50-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-chlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-51-3 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3-fluorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-52-4 CAPLUS

CN Cyclopropanecarboxamide, 1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-2-[(4-phenyl-1-piperidiny)methyl]-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-53-5 CAPLUS

CN Cyclopropanecarboxamide, 2-[(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-54-6 CAPLUS

CN Cyclopropanecarboxamide, 2-[[4-(acetylamino)-4-phenyl-1-piperidinyl]methyl]-1-(3,4-dichlorophenyl)-N-methyl-N-(1-naphthalenylmethyl)-, (1S,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 846060-76-2 CAPLUS

CN Cyclopropanecarboxamide, 2-[2-[4-(acetylamino)-4-phenyl-1-piperidinyl]ethyl]-1-(3,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-N-methyl-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AB An efficient, simple cheap, and environmentally benign preparation of cyclopropanes by 3-exo-trig manner from various electron-deficient 2-iodoethyl-substituted olefins with zinc powder in a mixture of t-Bu alc. and water was achieved.

ACCESSION NUMBER: 2004:1062615 CAPLUS

DOCUMENT NUMBER: 142:155563

TITLE: Facile and environmentally benign Zn-mediated cyclopropanation of electron-deficient 2-iodoethyl-substituted olefins via radical 3-exo-trig manner

AUTHOR(S): Sakuma, Daisuke; Togo, Hideo

CORPORATE SOURCE: Graduate School of Science and Technology, Chiba University, Chiba, 263-8522, Japan

SOURCE: Synlett (2004), (14), 2501-2504

CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:155563


IT 827574-06-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of cyclopropanes via zinc-mediated radical cyclopropanation of alkenyl halides)

RN 827574-06-1 CAPLUS

CN Ethanone, 2-(2,2-dimethylcyclopropyl)-1-(1-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

=>

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 18:51:56 ON 17 NOV 2008